We are live on ! Find out more
SLG

Stanley-Laman Group Portfolio holdings

AUM $814M
1-Year Est. Return 40.24%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+40.24%
3 Year Est. Return
+82.87%
5 Year Est. Return
+77.64%
10 Year Est. Return
+275.61%
AUM
$407M
AUM Growth
-$38.3M
Cap. Flow
-$52.4M
Cap. Flow %
-12.88%
Top 10 Hldgs %
19.3%
Holding
282
New
19
Increased
67
Reduced
110
Closed
63

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$6.14M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$5.93M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.36M
4
ALBO
Albireo Pharma Inc
ALBO
+$1.07M
5
ZYME icon
Zymeworks
ZYME
+$808K

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$8.83M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.78M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$4.57M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.53M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$966K

Sector Composition

Rank Sector Weight
1 Industrials 19.96%
2 Technology 18%
3 Healthcare 15.75%
4 Materials 7.84%
5 Financials 7.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRU icon
151
Prudential Financial
PRU
$41B
$711K 0.17%
7,019
+1,541
+28% +$152K
FONR
152
DELISTED
Fonar
FONR
$702K 0.17%
28,192
+851
+3% +$22.3K
RICK icon
153
RCI Hospitality Holdings
RICK
$201M
$685K 0.17%
23,128
+469
+2% +$14.9K
WY icon
154
Weyerhaeuser
WY
$17.3B
$681K 0.17%
21,088
+975
+5% +$33.8K
CCL icon
155
Carnival Corporation Ltd
CCL
$35.7B
$647K 0.16%
10,139
+191
+2% +$11.6K
UNM icon
156
Unum
UNM
$14.2B
$572K 0.14%
14,636
-553
-4% -$20.6K
ALB icon
157
Albemarle
ALB
$13.9B
$566K 0.14%
5,677
-512
-8% -$49.5K
INBK icon
158
First Internet Bancorp
INBK
$231M
$562K 0.14%
18,456
+373
+2% +$11.9K
VSEC icon
159
VSE Corp
VSEC
$5.46B
$553K 0.14%
16,698
+559
+3% +$22.9K
MAN icon
160
ManpowerGroup
MAN
$2.47B
$539K 0.13%
6,269
-473
-7% -$42.1K
WHG icon
161
Westwood Holdings Group
WHG
$183M
$531K 0.13%
10,255
+448
+5% +$25.7K
VEA icon
162
Vanguard FTSE Developed Markets ETF
VEA
$224B
$528K 0.13%
+12,202
New +$526K
AMZN icon
163
Amazon
AMZN
$2.69T
$491K 0.12%
4,900
+280
+6% +$26.3K
IJR icon
164
iShares Core S&P Small-Cap ETF
IJR
$109B
$458K 0.11%
5,254
+17
+0.3% +$1.49K
IWR icon
165
iShares Russell Mid-Cap ETF
IWR
$56.5B
$426K 0.1%
+7,728
New +$424K
REKR icon
166
Rekor Systems
REKR
$84.2M
$385K 0.09%
+315,625
New +$465K
VCIT icon
167
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
$66.5B
$382K 0.09%
4,573
-200
-4% -$16.8K
SHV icon
168
iShares 0-1 Year Treasury Bond ETF
SHV
$20.7B
$314K 0.08%
2,841
– –
MSFT icon
169
Microsoft
MSFT
$2.99T
$283K 0.07%
2,477
– –
FCN icon
170
FTI Consulting
FCN
$4.84B
$280K 0.07%
3,830
– –
IART icon
171
Integra LifeSciences
IART
$1.47B
$263K 0.06%
4,000
– –
KWR icon
172
Quaker Houghton
KWR
$2.57B
$243K 0.06%
+1,200
New +$210K
IWO icon
173
iShares Russell 2000 Growth ETF
IWO
$14.6B
$220K 0.05%
+1,022
New +$218K
BABA icon
174
Alibaba
BABA
$288B
$208K 0.05%
1,263
+60
+5% +$10.6K
MFC icon
175
Manulife Financial
MFC
$70.6B
$206K 0.05%
11,542
– –
5 6
7
8 9

Similar funds

VFG
Victory Financial Group Austin, Texas $814M AUM 18.17% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $816M AUM 34.73% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $812M AUM 17.34% 1-Year Est. Return
UAG
United Advisor Group Cincinnati, Ohio $811M AUM 18.32% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Stanley-Laman Group's Q3 2018 Portfolio in Review

As of Q3 2018, Stanley-Laman Group held 282 positions worth $407M, down 8.6% from $445M the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Stanley-Laman Group withdrew a net $52.4M in Q3 2018, closing 63 positions and reducing 110 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $8.83M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 20% of assets, up from 18% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Stanley-Laman Group opened a new position in Acceleron Pharma worth $7.16M.

  • Stanley-Laman Group's largest Q3 2018 buy was Acceleron Pharma: 125,020 shares worth $7.16M.
  • Stanley-Laman Group added most to Prudential Financial in Q3 2018, an estimated $152K increase.
  • Stanley-Laman Group's biggest Q3 2018 reduction was Hortonworks, Inc., cutting an estimated $629K.
  • Stanley-Laman Group fully exited Neurocrine Biosciences in Q3 2018, selling an estimated $8.83M.
  • Stanley-Laman Group's ten largest holdings make up 19% of its $407M portfolio in Q3 2018.
  • Stanley-Laman Group opened 19 new positions and closed 63 in Q3 2018.
  • Stanley-Laman Group's portfolio value fell 8.6% quarter-over-quarter to $407M.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.